Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

522 trials

NCT05327647
Recruiting
A Phase II Trial of Bicalutamide in Patients Receiving Intravesical BCG for Non-muscle Invasive Bladder Cancer
Phase 2 · Canada · 7 sites
Registry update: 26 Oct 2026
NCT05303532
Recruiting
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study with Durvalumab
Phase 3 · Belgium, Bulgaria, Czechia, Germany, Spain, France, Greece, Hungary, Italy, Poland, Romania · 54 sites
Registry update: 8 Sept 2026
NCT05302284
Recruiting
A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma
Phase 3 · China · 2 sites
Registry update: 18 Dec 2023
NCT05558111
Recruiting
The Supraspinal Control of Lower Urinary Tract Function in Patients With Orthotopic Sigmoid Neobladder.
Not applicable · China · 1 site
Registry update: 8 Oct 2026
NCT05415631
Recruiting
Augmented Bladder Tumor Detection Using Real Time Based Artificial Intelligence
Not applicable · France · 1 site
Registry update: 15 Jul 2022
NCT05366881
Recruiting
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Not applicable · United States · 17 sites
Registry update: 4 Nov 2026
NCT04879329
Recruiting
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Phase 2 · Argentina, Australia, Belgium, Canada, Chile, Spain, France, United Kingdom, Israel, Italy, Japan, United States · 221 sites
Registry update: 22 Jul 2026
NCT05337397
Recruiting
Outpatient Laser Ablation of Recurrent Non-muscle Invasive Bladder Cancer
Not applicable · Denmark · 1 site
Registry update: 8 Aug 2022
NCT06357416
Recruiting
The Man Van Project
Not applicable · United Kingdom · 1 site
Registry update: 1 May 2024
NCT05267626
Recruiting
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Phase 1/2 · Australia, United States · 17 sites
Registry update: 18 Sept 2026
NCT05296564
Recruiting
Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers
Phase 1/2 · Israel · 1 site
Registry update: 2 Oct 2025
NCT05269381
Recruiting
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
Phase 1/2 · United States · 1 site
Registry update: 20 Aug 2026
NCT04106115
Recruiting
DURvalumab in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancEr
Phase 1/2 · United Kingdom · 7 sites
Registry update: 11 Jun 2026
NCT05264337
Recruiting
Lymphedema After Urologic Surgery
Not applicable · Sweden · 2 sites
Registry update: 16 Jan 2026
NCT05621837
Recruiting
Quantifying Systemic Immunosuppression to Personalize Cancer Therapy
Not applicable · Italy · 1 site
Registry update: 2 May 2025
NCT05290038
Recruiting
ARON-2 Study-Multicentric International Retrospective Study
Not applicable · Italy · 1 site
Registry update: 2 Apr 2025
NCT05595408
Recruiting
Circulating and Urine Tumor DNA Dynamics Predict Minimal Residual Disease and Recurrence Risk in Locally Advanced Upper Tract Urothelial Carcinoma
Not applicable · China · 1 site
Registry update: 9 Dec 2025
NCT06652009
Recruiting
Radical Radiotherapy Versus Radical Surgery for UTUC
Not applicable · China · 2 sites
Registry update: 22 Oct 2024
NCT06598761
Recruiting
Postoperative Adjuvant Immunotherapy Combined with Radiotherapy Versus Surgery Alone in Locally Advanced UTUC
Not applicable · China · 2 sites
Registry update: 5 Nov 2024
NCT06652022
Recruiting
Radiotherapy Combined with Systemic Therapy Versus Systemic Therapy for Oligometastatic UTUCs
Not applicable · China · 2 sites
Registry update: 22 Oct 2024

Ordered by registry start date. Freshness and sponsorship never change the order.